Funded by the European Union

Understanding & overcoming therapy resistance in GI cancers

AdResCanCER is a multidisciplinary European initiative uniting researchers, clinicians,
innovators and industry to improve understanding of chemoresistance, accelerate innovation
and discovery, and develop clinically relevant solutions for gastrointestinal cancers.

Explore
mechanisms

Explore molecular drivers of GI cancer resistance

Connect
disciplines

Connect researchers across disciplines

Share
methods

Harmonize methodologies and share data

Support
translation

Support future research and clinical innovation

Why AdResCanCER?

Therapy resistance remains one of the most urgent challenges in gastrointestinal (GI) cancers. Although major advances have been made in targeted therapies and precision medicine, many patients eventually face treatment failure due to complex biological mechanisms that are still not fully understood. Overcoming this barrier requires coordinated effort, shared expertise, and a deeper understanding of the molecular and cellular processes driving resistance.

What’s in it for you?

AdResCanCER offers a collaborative environment designed to support scientific excellence and professional growth. By joining the network, researchers gain access to a multidisciplinary community working at the forefront of therapy resistance in GI cancers. Members benefit from increased visibility, opportunities for joint projects and funding applications, and access to shared expertise and resources.

WG1 – Genetic and Epigenetic Mechanisms

Understanding resistance where it begins: the genome.

WG2 – Tumour Microenvironment and Signalling Pathways

Understanding resistance beyond cancer cells: tissues, signals, and interactions.

WG3 – Therapeutic Approaches

Systems-level understanding of resistance mechanisms beyond tumour cells.

WG4 – Multi-OMICS Technologies

Integrating advanced OMICS technologies to improve diagnostics and biomarker discovery.

WG5 – Integrated Data Analyses and Machine Learning

Making sense of complex data to predict resistance and disease progression.

WG6 – Communication and Dissemination

Communicating progress, reporting results, and sharing impact.

Focus

Molecular drivers of GI cancer resistance

Activities

Mapping mutations, epigenetic regulation, and biomarkers

Outcomes

Shared knowledge, reviews, and coordinated research directions

Focus

Cellular, tissue, and microenvironmental drivers of adaptive resistance in GI cancers

Activities

Studying immune interactions, signalling pathways, non-malignant cells, and resistance-related biomarkers

Outcomes

Improved understanding of resistance mechanisms, identification of new therapeutic targets, and coordinated research outputs

Focus

Identification of novel microenvironment-associated therapeutic vulnerabilities

Activities

Development of network-wide methodological standards
Generation of joint publications and translational research proposals

Outcomes

Identification of promising therapeutic approaches, guidance for future clinical trials, and recommendations to improve treatment accessibility, Strengthened interdisciplinary collaboration.

Focus

Explore the advanced OMICS technologies for analysing GI cancers and treatment resistance

Activities

Mapping available OMICS tools, harmonising the analytical protocols, and developing integrated multi-OMICS workflows to mirror the focus aim

Outcomes

Standardised approaches, improved diagnostic and analytical pipelines, and support for the discovery of novel pathways/ biomarkers and drug targets

Focus

Integrated data analysis and machine learning approaches for GI cancer resistance

Activities

Harmonising multi-source datasets, developing and testing predictive models, and refining multilayer data analysis tools

Outcomes

Standardised data pipelines, predictive models to support biomarker and target discovery, and guidelines for reproducible data analysis

Focus

Communication, dissemination, and engagement around the Action’s activities and results

Activities

Managing the website and communication channels, producing dissemination materials, and coordinating outreach with stakeholders, policy makers, and patient organisations

Outcomes

Increased visibility of the Action, effective knowledge sharing across audiences, and sustained engagement within and beyond the scientific community

Participating Countries

  • COST member
  • COST member ITC

Latest news

all news

Breakthrough in Pancreatic Tumour Treatment

Scientists in Spain reported a new triple combination therapy that completely eliminated pancreatic tumours in mice without resistance developing — a step toward more durable treatment strategies. read more

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing! read more

Upcoming events

all events

Genomic & GI Cancer Workshop

12 JUN
12 Jun - 8:00 am GMT+0000
Register now

To top

Powered by
►
Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
None
►
Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
None
►
Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
None
►
Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
None
Powered by